Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | Ctnna1 |
| Gene Name: | Ctnna1 |
| Protein Full Name: | Catenin alpha-1 |
| Alias: | 102 kDa cadherin-associated protein;Alpha E-catenin;CAP102 |
| Mass (Da): | 100071 |
| Number AA: | 906 |
| UniProt ID: | P35221 |
| Locus ID: | 1495 |
| COSMIC ID: | Ctnna1 |
| Gene location on chromosome: | 5q31.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 21008 |
| Percent of cancer specimens with mutations: | 0.84 |
| Normal role description: | CTNNA1 is a catenin protein which mediates the association of the intracellular domains of cadherin proteins to the actin filaments of the cytoskeleton to form a stable adhesion complex. CTNNA1 is an alpha type catenin which preferentially interacts with epithelial type cadherin proteins (E-cadherins). CTNNA1 may form a homodimer that is proposed to regulate actin filament assembly by competing with the ARP2/3 complex to inhibit actin filament assembly. Dysfunction of the formation of the catenin-cadherin-actin adhesion complex has been implicated in increased cancer invasion and metastasis. In particular, dysfunction in CTNNA1 through mutational deletions was observed in lung cancer cell lines. CTNNA1 appears to function to inhibit the invasiveness of cancerous tumours with defects in CTNNA1 contributing to a worse prognosis in cancer progression. |
| Commentary on involvement of protein in cancer: | Less than 3% mutations in kidney cancers. |